Ahpra registration PHY0002298174
How these guides are written and reviewed →
Silicosis is a permanent scarring lung disease caused by inhaling fine crystalline silica dust, most often at work. It has re-emerged as a serious concern with the rise of engineered stone benchtop cutting, where extremely high silica levels can cause severe disease even after a few years of exposure. Silicosis cannot be cured or reversed, so prevention — dust control and protective equipment at work — is the priority, and early detection through health screening is important for anyone in a high-risk occupation. If you work or have worked in a Queensland mine, there is a specific screening scheme — see Mine Dust Lung Disease Screening.
Definition
Silicosis is an occupational lung disease caused by inhalation of fine respirable crystalline silica dust, leading to inflammation and permanent fibrotic scarring of lung tissue. It is one of the oldest recognised occupational lung diseases and has re-emerged prominently with the widespread use of engineered (composite) stone for kitchen and bathroom benchtops, which contains very high silica content and has produced severe disease in young workers after unusually short exposure.1
Pathophysiology
Inhaled silica particles small enough to reach the alveoli are engulfed by alveolar macrophages, which cannot break the crystals down and are themselves destroyed, releasing inflammatory mediators that drive a chronic fibrotic response. The freed crystals are re-ingested by new macrophages, so the cycle is self-sustaining — which is why disease can progress for years after exposure has ceased.
Over time this produces characteristic nodules of scar tissue, which in more severe or accelerated disease coalesce into large fibrotic masses (progressive massive fibrosis), destroying normal lung architecture and reducing lung function irreversibly.2
Three patterns of disease
- Chronic silicosis — after 10 or more years of lower-level exposure; the classical form.
- Accelerated silicosis — within 3–10 years of intense exposure; the pattern seen in engineered-stone workers.
- Acute silicosis (silicoproteinosis) — within weeks to a few years of extremely high exposure; rapidly progressive and frequently fatal.
Co-morbidities
Silicosis substantially increases the risk of active tuberculosis, because silica impairs the macrophage defence the body relies on against that organism. It is also associated with COPD and chronic bronchitis, autoimmune conditions including scleroderma and rheumatoid arthritis, chronic kidney disease, and lung cancer — silica is classified as a Group 1 human carcinogen independent of any accompanying smoking history.3
Prevalence
Silicosis historically affected miners, quarry and foundry workers, tunnellers and sandblasters. The past decade has seen a marked resurgence among younger tradespeople cutting, grinding and polishing engineered stone without adequate dust control, with clusters reported in Australia and internationally.4 Australia became the first country to prohibit the use of engineered stone, and disease continues to be detected through health surveillance of previously exposed workers.1
Causes and risk factors
Silicosis is caused by inhaling respirable crystalline silica generated by cutting, grinding, drilling, crushing or polishing silica-containing materials — engineered stone (which can exceed 90% silica), natural stone, concrete, brick, tile and sand. Risk depends on airborne dust concentration, the silica content of the material, duration of exposure, and the adequacy of dust suppression and respiratory protection. Dry cutting without extraction is the single highest-risk practice, and the absence of visible dust is not reassurance — the harmful fraction is invisible.1
Symptoms
Early disease
Often entirely asymptomatic, detected only on screening imaging. This is precisely why surveillance exists: symptoms are a late indicator, not an early one, and waiting for them means waiting for irreversible change.
Progressive disease
A persistent dry cough and gradually worsening exertional breathlessness develop, with more advanced or accelerated disease causing marked breathlessness, weight loss and respiratory failure.
Warning signs
Diagnosis
Why diagnosis matters
Diagnosis triggers the one intervention that changes the disease course — removal from exposure — and it opens access to compensation, retraining and surveillance. Late diagnosis forfeits all of these while the exposure continues.
How is it diagnosed?
A history of relevant silica exposure combined with characteristic imaging. No single test is confirmatory; the occupational history is as important as the radiology and is frequently the part that is not taken.2
Radiology
Chest X-ray shows small rounded nodules, typically upper-lobe predominant, sometimes with eggshell calcification of hilar nodes. High-resolution CT is considerably more sensitive and detects disease that plain films miss, which is why it is used in surveillance of high-risk workers rather than X-ray alone.
Lung function
Spirometry quantifies impairment and tracks progression, showing a restrictive, obstructive or mixed pattern depending on the disease pattern; gas transfer falls as fibrosis advances. Results are interpreted against current technical standards and reference equations, and a single normal spirometry does not exclude early disease.5
Health surveillance and screening
Structured screening of engineered-stone workers — occupational history, spirometry and low-dose CT — identifies disease at an early, asymptomatic stage in a meaningful proportion of those examined, which is the evidence base for surveillance programmes now mandated for this workforce.6
Investigations for related conditions
Screening for latent and active tuberculosis is recommended given the strongly increased risk, alongside autoimmune serology where clinically indicated and renal function testing.3
Management
Management and goals
There is no cure and no disease-modifying treatment that reverses established silicosis. The goals are to stop further exposure, treat what is treatable, maintain function, detect complications early, and support the person through a diagnosis that often arrives in their thirties or forties.
Removal from exposure
Immediate and permanent removal from further silica exposure is the essential first step and the only intervention that alters the trajectory. At population level, engineering controls, wet cutting, extraction, respiratory protection and regulatory exposure limits are the primary prevention strategy — and Australia's prohibition on engineered stone is the strongest of these measures.7
Supportive care
Treatment of coexisting airflow obstruction, influenza and pneumococcal vaccination, smoking cessation support, and screening and treatment for tuberculosis. Pulmonary rehabilitation is offered on the same basis as for other fibrotic lung disease.2
Advanced disease
Long-term oxygen therapy for chronic hypoxaemia, and assessment for lung transplantation in selected younger patients with severe disease — a realistic consideration in engineered-stone silicosis precisely because the affected group is young and otherwise well.
Identifying deterioration
Increasing breathlessness, falling exercise tolerance, weight loss, fever or haemoptysis all warrant review rather than being attributed to known disease.
Action plan
- Cease all further silica exposure — this includes hobby and home renovation work, not only paid employment.
- Attend all scheduled respiratory reviews and imaging, including when you feel well.
- Report fever, night sweats, weight loss or coughing blood immediately — tuberculosis risk is materially raised.
- Keep vaccinations current and do not smoke.
- Pace activity to breathlessness rather than stopping activity altogether.
- Pursue the workers' compensation and dust-disease scheme entitlements you qualify for — these are time-sensitive.
Medications
There is no disease-modifying drug
No pharmacological therapy halts or reverses silicotic fibrosis. Antifibrotic agents used in idiopathic pulmonary fibrosis do not have an established role here, and should not be presented as an option outside a trial.
Treating airflow obstruction
Inhaled bronchodilators, with or without inhaled corticosteroid, are used where obstruction coexists — common given the overlap with dust-related COPD. Correct inhaler technique is checked and re-checked.
Tuberculosis
Treatment of latent or active tuberculosis follows standard regimens, with a lower threshold for investigation than in the general population.
Vaccination
Annual influenza, pneumococcal and COVID-19 vaccination are recommended given the elevated risk of respiratory infection and its consequences in fibrotic lung disease.
Multi-system manifestations
Autoimmune disease
Silica exposure is a recognised trigger for systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosus and ANCA-associated vasculitis. New joint, skin or renal symptoms in a silica-exposed worker are investigated rather than attributed to the lungs.
Kidneys
Silica nephropathy and glomerulonephritis are described, sometimes in association with vasculitis, and renal function is monitored as part of follow-up.
Infection
Impaired macrophage function raises susceptibility to tuberculosis and non-tuberculous mycobacterial infection markedly, and the risk persists lifelong after exposure ends.
Cancer
Crystalline silica is a Group 1 carcinogen, and lung cancer risk is raised independently of smoking — a point that matters when counselling non-smoking workers who assume they are unaffected.3
Living with silicosis
Stopping exposure
Complete cessation of exposure, including in unpaid and hobby settings, is the foundation of everything else. Where a person's trade is the exposure, this is a livelihood decision as much as a medical one.
Staying active
Pulmonary rehabilitation improves exercise capacity, breathlessness and quality of life in interstitial lung disease, and is applied to silicosis on that basis.8 Benefits attenuate over months without a maintenance programme, so the plan continues past the supervised block.
Oxygen
Ambulatory oxygen improves quality of life in people with fibrotic lung disease and exertional desaturation, and is assessed formally rather than assumed.9
Work, compensation and identity
Engineered-stone silicosis typically affects tradespeople in their thirties and forties, and the diagnosis ends a career as well as changing health. Compensation processes, retraining and income support are part of care, and are time-limited — raising them early is practical help, not overreach.
Mental health
An incurable, potentially progressive diagnosis in a young worker carries a substantial psychological burden, frequently compounded by anger at preventable exposure. Palliative and supportive care principles apply well before end-of-life, and early involvement improves symptom control and quality of life in fibrotic lung disease.10
Prognosis
Simple chronic silicosis with limited exposure may remain stable for years once exposure stops. Accelerated and acute silicosis, as seen in some engineered-stone workers, can progress rapidly to significant disability or progressive massive fibrosis within a few years, and disease can advance despite exposure having ceased.2 Silicosis shortens life expectancy in more severe cases, chiefly through progressive respiratory failure, tuberculosis or lung cancer. Because the affected population is young, planning that includes transplantation assessment and supportive care runs in parallel rather than in sequence.10
Role of the physiotherapist
The physiotherapist delivers pulmonary rehabilitation to address breathlessness, deconditioning and exercise tolerance,8 supports airway clearance where chronic bronchitis or bronchiectasis coexist, assesses exertional desaturation and the response to ambulatory oxygen,9 and teaches breathlessness-management and pacing strategies for daily life.
Beyond the physical, physiotherapists are often the clinician a young worker sees most regularly. That position makes them well placed to reinforce the absolute importance of ceasing exposure, to notice the symptoms that suggest tuberculosis or progression, and to support the vocational and psychological adjustment involved — working alongside occupational physicians, respiratory teams and compensation processes.10
Physiotherapy red flags — stop and escalate: fever, night sweats or weight loss; haemoptysis; new or rapidly worsening breathlessness; and significant exertional desaturation during assessment.
Part 1 · References
- Hoy RF, Baird T, Hammerschlag G, et al. Artificial stone-associated silicosis: a rapidly emerging occupational lung disease. Occup Environ Med 2018;75(1):3–5.
- Leung CC, Yu ITS, Chen W. Silicosis. Lancet 2012;379(9830):2008–2018.
- International Agency for Research on Cancer. Silica dust, crystalline, in the form of quartz or cristobalite. IARC Monogr Eval Carcinog Risks Hum 2012;100C:355–405.
- Rose C, Heinzerling A, Patel K, et al. Severe silicosis in engineered stone fabrication workers — California, Colorado, Texas, and Washington, 2017–2019. MMWR Morb Mortal Wkly Rep 2019;68(38):813–818.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update: an official ATS and ERS technical statement. Am J Respir Crit Care Med 2019;200(8):e70–e88.
- Hoy RF, Glass DC, Dimitriadis C, Hansen J, Hore-Lacy F, Sim MR. Identification of early-stage silicosis through health screening of stone benchtop industry workers in Victoria, Australia. Occup Environ Med 2021;78(4):296–302.
- Safe Work Australia. Prohibition on the use of engineered stone: model WHS regulations. Canberra: Safe Work Australia; 2024.
- Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021;(2):CD006322.
- Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 2018;6(10):759–770.
- Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med 2017;5(12):968–980.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
More than one of our services applies here, and which combination suits you depends on what your assessment shows.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Silicosis is entirely preventable and has no disease-modifying treatment, which puts the whole clinical weight on exposure control, early detection and supportive management.1 Australia has lived through a rapid epidemic of artificial-stone silicosis in benchtop workers — younger patients, shorter latency, accelerated and complicated disease — which led to a national prohibition on the use, supply and manufacture of engineered stone from July 2024.2,3,4
Disease behaviour and detection
- Artificial-stone silicosis presents differently: Victorian screening of stone benchtop workers found substantial rates of disease including early-stage cases in symptom-free workers, confirming the value of active health surveillance over symptom-triggered presentation.2
- Progression can continue after exposure ends, so removal from exposure prevents further insult but does not guarantee stability — a point patients must understand.5
- Complicated silicosis (progressive massive fibrosis) and accelerated forms carry a poor prognosis, with lung transplantation the only definitive option in advanced disease.1,5
- Silica exposure raises other risks: tuberculosis, lung cancer (silica is a group 1 carcinogen), autoimmune disease including systemic sclerosis and rheumatoid arthritis, and chronic kidney disease.1,6
- Surveillance uses spirometry plus imaging, with high-resolution or low-dose CT more sensitive than chest radiography for early nodular disease; correct spirometric technique and reference equations matter.2,7
Supportive and rehabilitative management
- Pulmonary rehabilitation improves exercise capacity, dyspnoea and quality of life in fibrotic lung disease, and is applied here by extension — there are no silicosis-specific trials.8
- Ambulatory oxygen improved quality of life in fibrotic lung disease with exertional desaturation, and supplemental oxygen permits higher training work rates in desaturating patients.9
- Airway clearance has no routine role; reserve it for coexisting bronchiectasis, chronic bronchitis or a documented retention problem.
- Breathlessness management, pacing and anxiety strategies carry most of the symptomatic benefit in advanced disease, as in other progressive fibrotic conditions.8,10
- Early transplant referral matters in accelerated disease, and maintaining conditioning, weight and function is part of remaining a candidate.5
Physiotherapy implications
- Take the occupational history in detail — every job, materials, dry versus wet cutting, ventilation, respiratory protection and duration. It determines diagnosis, notification, compensation and whether colleagues are still being exposed.1,2
- Refer for surveillance and specialist assessment rather than treating breathlessness in a stone, mining, tunnelling, quarrying or construction worker as deconditioning.2
- Prescribe for a desaturating fibrotic patient: interval training, oximetry, oxygen where prescribed, and progression judged on symptoms and recovery rather than a saturation floor.9
- Include resistance training for corticosteroid-related and disuse weakness, and address weight and nutrition.
- Support the young worker's whole situation: loss of trade, income, identity and future employability drives the mental-health burden in this cohort as much as the breathlessness does — signpost compensation, dust-diseases schemes and psychological support.3
- Reinforce exposure control where work continues: engineering controls first (wet cutting, local exhaust ventilation, enclosure), then fit-tested respiratory protection — never dry cutting.4
- Escalate rapid progression, new resting hypoxaemia, weight loss, haemoptysis or fever (consider tuberculosis and malignancy, both over-represented here).6
Clinical reasoning
- A young worker with breathlessness and abnormal imaging is a dust-disease question until proven otherwise; assuming youth excludes fibrosis is the classic source of diagnostic delay.2
- One diagnosed worker implies a workplace, so "who else works there?" belongs in the referral letter.
- Falling walk distance between visits is progression and should be reported, not absorbed into the programme.
- Frame goals around function, symptom control and what matters to the patient — capacity lost to fibrosis will not be restored.10
Evidence gaps
- No rehabilitation trial exists in silicosis; the entire prescription is extrapolated from IPF and COPD populations.8
- Progression rates and predictors in artificial-stone silicosis are still being characterised in cohorts.2
- Optimal surveillance interval and imaging modality after exposure ceases are unresolved.7
- Whole-lung lavage and other experimental interventions lack controlled evidence.1
Queensland mine workers fall under a statutory health surveillance scheme with its own respiratory function, imaging and referral requirements — see Mine Dust Lung Disease — Clinical Pathways for the current pathway and escalation triggers.
References for the clinical evidence summary
- Leung CC, Yu ITS, Chen W. Silicosis. Lancet 2012;379(9830):2008–2018.
- Hoy RF, Glass DC, Dimitriadis C, Hansen J, Hore-Lacy F, Sim MR. Identification of early-stage silicosis through health screening of stone benchtop industry workers in Victoria, Australia. Occup Environ Med 2021;78(4):296–302.
- Hoy RF, Baird T, Hammerschlag G, et al. Artificial stone-associated silicosis: a rapidly emerging occupational lung disease. Occup Environ Med 2018;75(1):3–5.
- Safe Work Australia. Prohibition on the use of engineered stone: model WHS regulations. Canberra: Safe Work Australia; 2024.
- Rose C, Heinzerling A, Patel K, et al. Severe silicosis in engineered stone fabrication workers — California, Colorado, Texas, and Washington, 2017–2019. MMWR Morb Mortal Wkly Rep 2019;68(38):813–818.
- International Agency for Research on Cancer. Silica dust, crystalline, in the form of quartz or cristobalite. IARC Monogr Eval Carcinog Risks Hum 2012;100C:355–405.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update: an official ATS and ERS technical statement. Am J Respir Crit Care Med 2019;200(8):e70–e88.
- Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021;(2):CD006322.
- Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 2018;6(10):759–770.
- Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med 2017;5(12):968–980.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.